KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to -$184.2 million.

  • Alnylam Pharmaceuticals' Change in Receivables fell 40961.72% to -$184.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $360.0 million, marking a year-over-year increase of 31590.18%. This contributed to the annual value of $360.0 million for FY2025, which is 31590.18% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Change in Receivables stood at -$184.2 million, which was down 40961.72% from $399.9 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Change in Receivables high stood at $399.9 million for Q3 2025, and its period low was -$184.2 million during Q4 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Change in Receivables value was $9.1 million (recorded in 2021), while the average stood at $34.1 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Change in Receivables crashed by 47067.89% in 2022 and then soared by 191317.07% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Change in Receivables (Quarter) stood at $59.4 million in 2021, then fell by 10.4% to $53.3 million in 2022, then tumbled by 107.26% to -$3.9 million in 2023, then soared by 1638.07% to $59.5 million in 2024, then crashed by 409.62% to -$184.2 million in 2025.
  • Its last three reported values are -$184.2 million in Q4 2025, $399.9 million for Q3 2025, and $136.9 million during Q2 2025.